Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

The note reveals that Goldman has initiated coverage with a buy rating and $48.90 price target on ResMed's shares. Based on ...

In a report released today, Mathieu Chevrier from Citi maintained a Hold rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs ...

The fourth-quarter 2024 earnings season will kick off this week, with banking sector players due to report numbers. The ...

Goldman Sachs has initiated coverage on medical equipment maker ResMed and biotech giant CSL with a ‘buy’ ratings as analysts ...

Three Australian fund managers who delivered annualised double-digit returns over the past 10 years share their views on what ...

If you are looking for a profitable portfolio of stocks offering the best of value and growth investing, try the growth at a reasonable price or GARP strategy. The strategy helps investors gain ...

According to the latest Earnings Trends report, total S&P 500 earnings are expected to be up 7.4% from the year-ago period on ...

Sleep and respiratory disorders sector of the medical device industry ("Sleep and Respiratory Care') and the supply of business management software as a service to out-of-hospital health providers ...

Across two phase 3 trials, Zepbound reduced OSA episodes in both participants using positive airway pressure (PAP), the standard of care for moderate to severe OSA, which involves wearing a mask ...